Skip to main content

Table 1 Baseline characteristics of 13 non-comparative studies and patients

From: Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis

Authors (year) [Ref] Study Design Region Patients CPS BCLC ECOG Aetiology Treatment No. of TACE Duration Time of sorafenib
Erhardt et al. (2014) [33] Phase II Germany 38 ≤8scores NA 0–2 NA Continuous sorafenib, interrupted only around TACE 2.0(mean) NA
Dufour et al. (2010) [34] Phase I Open-label Switzerland 14 A = 93% B = 7% B = 64% C = 36% 0 = 93% 1 = 7% HCV = 29% Sorafenib started 1 week prior to TACE without pause for TACE 2.0(median) NA
Cabrera et al. (2011) a [35] Phase II Prospective USA 47 A = 72% B = 28% B = 81% C = 19% 0 = 75% 1 = 25% HCV = 60% Continuous sorafenib started 2–4 weeks before DEB-TACE 3.0(median) NA
Lee et al. (2011) [36] Phase II Prospective South Korea 59 A = 93% B = 7% B = 100% NA HBV = 88% Sorafenib, TACE was performed at every 6–8 weeks NA NA
Pawlik et al. (2011) a [37] Phase II Prospective USA 35 A = 89% B = 11% B = 34% C = 66% 0 = 46% 1 = 54% HCV = 37% Continuous sorafenib started 1 week before DEB-TACE 2.0(median) NA
Park et al. (2012) [38] Phase II Prospective South Korea 50 A = 94% B = 6% B = 82% C = 18% 0 = 44% 1 = 56% HBV = 68% HCV = 18% Sorafenib started 3 days after TACE 1.0(median) 6 month
Sieghart et al. (2012) [39] Phase I Austria 15 A = 80% B = 20% B = 70% C = 30% 0 = 92% 1 = 8% HBV = 4% HCV = 20% Sorafenib started 2 weeks before the first TACE 3.0(median) 5.2 month (median)
Chung et al. (2013) [40] Phase II Prospective China and South Korea 151 A = 92% B = 8% A = 16% B = 82% C = 1.9% 0 = 82% 1 = 18% NA Sorafenib started 4–7 days after TACE 2.1(mean) NA
Zhao et al. (2013) [41] Prospective China 222 A = 86% B = 14% B = 20% C = 80% 0 = 44% 1 = 50% 2 = 6% HBV = 80% HCV = 5% Continuous sorafenib with no breaks before or after TACE 2.0(median) NA
Pan et al. (2014) [7] Retrospective China 41 A = 85.4% B = 14.6% NA 0 = 48.8% 1 = 51.2% HBV = 97.6% HCV = 2.4% Sorafenib was taken 3 days after the first TACE procedure 2.0(median) NA
Chao et al. (2014) [2] Phase II Prospective Taiwan 192 A = 91.8% B = 7.1% A = 16.9% B = 81.5% C = 1.6% 0 = 81.8% 1 = 17.7% 3 = 0.5% NA Sorafenib on day 4 (to day 7) after the first TACE (day 1) the interrupt on day 4 before the next TACE 3.0(median) NA
Yao et al. (2015) [32] Retrospective China 50 A = 88% B = 12% B = 52% C = 48% 0 = 46% 1 = 54% HBV = 84% HCV = 4% Sorafenib before and after 1 week of TACE 3.0(median) 1.4 month (median)
Cosgrove et al. (2015) a [42] Phase II USA 50 A = 92% B = 8% A = 6% B = 32% C = 62% 0 = 52% 1 = 48% HBV = 8% HCV = 44% Sorafenib was started 1 week before the first round of DEB-TACE 2.0(median) 1.5 month
  1. Abbreviations: BCLC The Barcelona Clinic Liver Cancer, CPS Child-Pugh classification, ECOG Eastern Cooperative Oncology Group, NO. number, NA not available, HBV hepatitis B virus, HCV hepatitis C virus
  2. a TACE with drug-eluting beads (DEB) was performed in the studies. Patients in other studies treated with conventional TACE (c-TACE)
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us

\